AstraZeneca schließt strategische Kooperationsvereinbarung mit CSPC Pharmaceuticals über globale Rechte an Gewichtmanagement-Portfolio
I'm PortAI, I can summarize articles.
AstraZeneca plc has announced a strategic cooperation agreement with CSPC Pharmaceuticals for global rights to its weight management portfolio. The company has also entered into an agreement with AbelZeta for worldwide rights to develop, manufacture, and market C-CAR031, with potential payments up to $630 million. Additionally, AstraZeneca has partnered with Jacobio Pharma on the JAB-23E73 pan-KRAS inhibitor program, gaining exclusive rights outside China, while both companies will co-develop it in China. Jacobio will receive a $100 million upfront payment and potential milestone payments.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments